Lyra Therapeutics (LYRA) Announces Appointment of Robert Kern, MD, as Chief Medical Officer
- Tech stocks push S&P 500 to record close, buoy Nasdaq
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Coinbase (COIN) direct listing IPO reference price set at $250
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil rises after robust China data but J&J vaccine pause weighs
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Robert Kern, MD has been named Chief Medical Officer. He will also remain in his current position as the George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery, Northwestern University Feinberg School of Medicine. Dr. Kern is the immediate past president of the American Rhinologic Society and current President of the International Society of Inflammation and Allergy of the Nose. He is a highly regarded clinician and researcher with a long history of leadership in the field of sinonasal disorders.
“We are excited to welcome Dr. Kern, who is a renowned physician in the ENT field and a world-leading expert in chronic rhinosinusitis, to the Lyra team as our Chief Medical Officer, to oversee the development of our clinical pipeline,” said Maria Palasis, PhD, CEO of Lyra Therapeutics. “Dr. Kern has a proven track record of global leadership in otolaryngology, in both academic research and clinical rhinology, that we believe will prove invaluable to Lyra’s successful development of LYR-210 and LYR-220.”
“I know firsthand the enormous need for new treatment options for CRS patients, and I am enthusiastic to guide the next phase of clinical development for LYR-210 and LYR-220,” said Dr. Kern. “Lyra established a clear proof of concept for LYR-210 with the recent positive LANTERN Phase 2 results, and I am pleased to join the dynamic leadership team to help advance Lyra’s next stage of growth as we work together to address the needs of underserved patients chronically suffering with CRS.”
Dr. Kern has 30 years of experience in the ENT medical field. He joined the Northwestern faculty over two decades ago, and was appointed as Chair of the Department of Otolaryngology in 2006. His ENT clinical practice focuses around complex sinonasal disease and endoscopic skull base surgery and he has authored more than 200 peer-reviewed articles.
Dr. Kern attended medical school at the Jefferson Medical College of Thomas Jefferson University and completed an otolaryngology residency at Wayne State University as well as a two-year National Institutes of Health (NIH) research training fellowship. He has an undergraduate degree from Georgetown University.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax (NVAX) announces Gale E. Smith, Ph.D. promoted to Senior Vice President, Greg Covino to step down as CFO
- AdaptHealth (AHCO) has placed Luke McGee on unpaid leave from his roles as Co-CEO and Director
- AppHarvest (APPH) Announces Ciara Burnham and Geof Rochester to Board
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!